Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Eicosapentaenoic acid is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms. The major product of this epoxygenase pathway, (±)17(18)-EpETE , relaxes vascular and airway smooth muscle by activating large conductance Ca2+-activated K+ (BKCa) channels by directly interacting with BKα channel subunits. (±)8(9)-EpETE is an epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo. The biological actions and physiological effects of this epoxide remain to be determined.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 μg | 35 days | $ 120.00 | |
50 μg | 35 days | $ 223.00 | |
100 μg | 35 days | $ 420.00 | |
500 μg | 35 days | $ 1,840.00 |
Description | Eicosapentaenoic acid is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms. The major product of this epoxygenase pathway, (±)17(18)-EpETE , relaxes vascular and airway smooth muscle by activating large conductance Ca2+-activated K+ (BKCa) channels by directly interacting with BKα channel subunits. (±)8(9)-EpETE is an epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo. The biological actions and physiological effects of this epoxide remain to be determined. |
Molecular Weight | 318.457 |
Formula | C20H30O3 |
CAS No. | 851378-93-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 50 mg/mL
DMSO: 50 mg/mL
DMF: 50 mg/mL
PBS (pH 7.2): 1 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(±)8(9)-EpETE 851378-93-3 8(9)-EpETE (±)8(9) EpETE (±)8(9)EpETE inhibitor inhibit